SYDNEY, Australia and BEDMINSTER, N.J., May 22 /PRNewswire-FirstCall/
-- QRxPharma Limited (ASX: QRX), a clinical-stage specialty pharmaceutical
company focused on the development and commercialisation of therapies for
pain and central nervous system (CNS) disorders, announced today additional
Phase 3 data for Q8003IR establishing a 12mg/8mg morphine and oxycodone
combination as the preferred dose for optimal efficacy and tolerability.

"While the initial Phase 3 efficacy data demonstrated statistically
significant pain reduction activity of Q8003IR at all dose levels, further
analysis suggests that the 12mg/8mg dose delivers the best analgesic effect
and tolerability profile," said Dr. John Holaday, Managing Director and
Chief Executive Officer, QRxPharma. "These data confirm that our patented
dual opioid combination of morphine and oxycodone provides synergistic
effects on pain relief and is able to achieve equal or better analgesia at
materially lower doses than the active opioid comparator while
simultaneously reducing incidence levels of specific side effects."

The goal of the double-blind, placebo-controlled Phase 3 study was to
compare four different dosage regimens of Q8003IR in patients with moderate
to severe post-surgery pain (bunionectomy) and establish the preferred dose
parameters. Secondary endpoints included: (1) efficacy relating to the time
to onset of analgesia and the duration of effect from a single oral dose
and (2) safety as measured by the incidence and intensity of opioid-related
adverse events.

Of the patients receiving 12mg/8mg dose of morphine/oxycodone, 58%
reported good to excellent global improvement (as compared to 13% for
placebo) and demonstrated the greatest dose-response effect (p<0.0003) in
terms of reducing pain intensity scores as well as other measures of
analgesic effect.

Post-surgery and prior to the first 12mg/8mg dose of Q8003IR, the
baseline patient pain intensity (PI) scores averaged 6.6 out of 10 units --
with 10 being the most severe on the Numerical Pain Rating Scale. Analgesic
effects as reflected in the maximum pain improvement (PI) for the 12mg/8mg
dose of Q8003IR yielded a 2 unit reduction of PI (decreasing patient scores
to 4.6) versus a 0.14 unit increase of PI for placebo-treated patients.
Placebo patients were treated with ibuprofen, a non-opioid analgesic.

The mean time to confirmed perceptible pain relief for Q8003IR was 42
minutes compared to 4.4 hours for placebo. The duration time of analgesic
effect was 6.6 hours for Q8003IR versus 2.8 hours for placebo.

The 12mg/8mgdose data demonstrated that Q8003IR was well tolerated,
with a low rate of patient withdrawal (8% discontinuing use due to adverse
events and 6% discontinuing use due to efficacy failure) compared to
placebo (with 2% discontinuing use due to adverse events and 25%
discontinuing use for efficacy failure). Only 2% of 12mg/8mg Q8003IR
treated patients experienced somnolence, and no incidences of euphoria were
reported. The low level of somnolence and absence of euphoria reported were
unexpected outcomes compared to what is typically seen with morphine or
oxycodone. The significance of these observations will need to be confirmed
in future studies that provide a direct data comparison.

All patients exhibited acceptable respiratory rates with reduction in
blood oxygen levels occurring in less than 2% of those on the preferred
dose of Q8003IR. Typical of opioid drugs, nausea and vomiting were the most
common adverse events. Of patients receiving the 12mg/8mg dose, 56%
experienced mild to moderate nausea that diminished over the first few
hours of treatment; no incidences of severe nausea were reported. 32% of
patients reported vomiting with initial dosing (18% mild to moderate and
14% severe). 20% of patients experienced mild to moderate dizziness; no
incidences of severe dizziness were reported.

Q8003IR is an immediate release dual opioid product candidate intended
for the acute management of moderate to severe pain, a $2.5 billion dollar
market in the U.S. alone. This patent-protected combination of morphine and
oxycodone has been clinically shown to provide synergistic effects on pain
relief with a significant reduction of total opioid dose and side effects.
Final Phase 3 studies with Q8003IR will be initiated shortly to complete
the required data package for New Drug Application (NDA) submission to the
US Food and Drug Administration (FDA) in 2009 as planned.

Forward Looking Statements

This press release contains forward-looking statements that involve
risks and uncertainties. The forward-looking statements contained herein
represent the judgment of QRxPharma as of the date of this release. These
forward-looking statements are not guarantees for future performance.
Actual results could differ materially from those currently anticipated to
due to a number of factors including risks relating to the stage of
products under development; uncertainties relating to clinical trials;
dependence on third parties; future capital needs; and risks relating to
the commercialisation of the Company's proposed products.

About QRxPharma

QRxPharma (ASX: QRX) is a clinical-stage specialty pharmaceutical
company focused on the development and commercialisation of new treatments
for pain management and central nervous system (CNS) disorders. Based on a
development strategy which focuses on enhancing and expanding the clinical
utility of currently marketed compounds, the Company's product portfolio
includes both late and early stage clinical drug candidates with the
potential for reduced risk, abbreviated development paths, and improved
patient outcomes. The Company intends to directly commercialise its
products in the U.S. and seek strategic partnerships abroad. QRxPharma's
lead compound, Q8003IR, successfully completed a Phase 3 study and met
primary and secondary endpoints. The Company's preclinical and clinical
pipeline includes other technologies in the fields of pain management,
neurodegenerative disease and venomics. For more information:
http://www.QRxPharma.com.

(Date:12/8/2016)... ... December 08, 2016 , ... Peter Zipp Insurance, ... and around the greater Phoenix metropolitan region, is announcing a charity event to ... of the Homeless Youth Connection is to promote community awareness of the ongoing ...

(Date:12/8/2016)... Louis, MS (PRWEB) , ... December 08, 2016 , ... ... that serve commercial and residential clients in and around the Hancock County area, is ... for the Hancock County Food Pantry. , The Hancock County Food Pantry has worked ...

(Date:12/8/2016)... ... December 08, 2016 , ... Bill Mull ... business owners in and around central Kansas, is joining the Youth Horizons organization ... the region. , Headquartered in Wichita, Youth Horizons works to empower area children ...

(Date:12/7/2016)... ... December 07, 2016 , ... Students ... have the unique opportunity to get hands-on experience in an emergency medical simulation, ... immersive experience to gain invaluable, real-life medical skills that are critical success in ...